1 Min Read
Sept 5 (Reuters) - Novartis Ag
* Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS Further company coverage: (Reporting by Zurich Newsroom)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.